Understanding HCV Nonresponse and Identifying Candidates for Retreatment
Source: New Management Strategies for HCV Nonresponders and Relapsers


Mitchell L. Shiffman, MD, reviews the various types of virologic response in hepatitis C virus–infected patients treated with interferon and ribavirin-based regimens and explains how to identify patients who would be good candidates for retreatment if they fail to achieve sustained virologic response.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Specify standard definitions of response and nonresponse to hepatitis C virus therapy
  • Discuss factors associated with nonresponse to hepatitis C virus therapy
  • Report criteria that may help to identify nonresponders who are good candidates for retreatment
  • Summarize data from studies of different retreatment strategies
  • Describe appropriate virologic goals of therapy for nonresponders undergoing retreatment

Topics covered include:

  • Introduction
  • Defining the Patterns of Virologic Response and Nonresponse
  • Rapid Virologic Response
  • Achieving Undetectable HCV RNA After Week 4 and Slow Virologic Response
  • Early Virologic Response and Nonresponse Virologic Patterns
  • Breakthrough and Relapse
  • Identifying Candidates for Retreatment: Null Response
  • Identifying Candidates for Retreatment: Partial Virologic Response
  • Identifying Candidates for Retreatment: Noncompliance, Medication Errors and Dose Reduction
  • Identifying Candidates for Retreatment: Failure to Recognize That Virologic Response Has Occurred
  • Identifying Candidates for Retreatment: Insufficient Treatment Duration
  • Conclusions
  • Summary of Clinical Implications


  • Mitchell L. Shiffman

Credit Information

  • Release Date:
    October 04, 2007
  • Expiration Date:
    October 03, 2008
  • Physicians:
    maximum of 1.0 AMA PRA Category 1 Credit
  • Registered Nurses:
    1.0 Nursing contact hour
  • Don’t Marginalize Your HCV-Infected PWID—Treat Them

    Jason Grebely BSc, PhD - 9/16/2013    1 comment / Last Comment: 10/8/2013
    Even people who use drugs can achieve successful outcomes with hepatitis C therapy, with low reinfection rates.
  • Drug Users and HCV Providers: How Do We Work Together to Achieve HCV Treatment Success?

    Gregory Dore  - 9/24/2013    2 comments / Last Comment: 11/9/2013
    Injecting drugs is a path to hepatitis C infection, but that path is not a dead end when providers join the journey to a cure with careful patient selection and understanding.
  • Coffee May Offer Real Benefits to the Liver

    Mark S. Sulkowski MD - 8/13/2013    7 comments / Last Comment: 11/30/2013
    The latest prescription for liver health in patients with hepatitis: coffee.
  • Post-CROI Update: How I Manage HIV/HCV-Coinfected Patients

    Jürgen K. Rockstroh MD - 4/9/2014    
    How should HIV treaters apply the latest HCV study results and guidelines to the management of coinfected patients?
  • Enter the Nonspecialist: Will Evolving Hepatitis C Therapies Reduce the Need for Specialized Care?

    Graham R. Foster FRCP, PhD - 10/8/2013    20 comments / Last Comment: 2/5/2014
    As therapeutic options for hepatitis C therapy evolve with reduced dosing requirements and improved adverse event profiles, the need for specialist care will diminish.